Abstract
The programmed death 1 (PD-1) receptor is a T-cell surface molecule that inhibits effector T cells if engaged with its ligand, PD-L1, on the surface of cancer cells. This restriction allows malignant cells to escape immune destruction. Recently, both the anti–PD-1 antibody nivolumab (formerly known as BMS936558) and the anti–PD-L1 antibody BMS936559 showed significant antitumor activity in patients with advanced melanoma (and other cancers). Researchers conducted a follow-up trial of the safety of and response …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
